HIV/AIDS Pharmaceutical Research
Extended-release clarithromycin well tolerated and bioequivalent to IR formulation
Published in AIDS Weekly, February 27th, 2006
"Clarithromycin is a key agent in effective antimycobacterial therapy and prophylaxis for AIDS-related disseminated Mycobacterium avium complex (dMAC) infection. Immediate-release (IR) clarithromycin tablets are dosed at 500 mg bid for these indications," scientists writing in the journal HIV Clinical Trials report.
According to the authors, "A new extended-release (ER) tablet of clarithromycin has been developed and approved at a dosing interval of once every 24...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-02-27)
More Articles from AIDS Weekly
- HIV/AIDS Genetics & Genomics
Genetic variants in associated host genes may play important role in HIV-1 susceptibility - HIV/AIDS HAART
HIV-1 K103N mutation after HAART withdrawal has little impact on viral fitness - HIV/AIDS HAART
Three of 8 mutations in ATV/RTV genotypic resistance score predict reduced response - HIV/AIDS Healthcare Costs
Feasible to effectively treat same number of patients at same or lower cost per patient - HIV/AIDS Therapy
Sequencing antiretroviral drugs extends the suppression of HIV replication - Awards
Kaiser Foundation, CNN International announce new award for HIV/AIDS journalism in Africa - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
